

# Jing Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1285039/publications.pdf>

Version: 2024-02-01

15  
papers

776  
citations

1040056

9  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1027  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 141-148.   | 2.3  | 4         |
| 2  | TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1 $\alpha$ degradation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 44. | 8.6  | 25        |
| 3  | An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 683-695.  | 2.3  | 6         |
| 4  | <i>ZNF582</i> promoter methylation predicts cervical cancer radiosensitivity and ZNF582 protein overexpression reduces radiosensitivity by cell cycle arrest in S phase. <i>Epigenetics</i> , 2022, 17, 1786-1799.                                | 2.7  | 1         |
| 5  | Development of a novel transcription factors-related prognostic signature for serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 7207.  | 3.3  | 8         |
| 6  | PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. <i>Redox Biology</i> , 2021, 42, 101928.  | 9.0  | 150       |
| 7  | Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 644-652.   | 0.1  | 0         |
| 8  | Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. <i>Modern Pathology</i> , 2020, 33, 29-37.  | 5.5  | 28        |
| 9  | Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 780-791.  | 5.1  | 49        |
| 10 | PARP inhibitor resistance: the underlying mechanisms and clinical implications. <i>Molecular Cancer</i> , 2020, 19, 107.  | 19.2 | 235       |
| 11 | Comparison of survival outcomes of neoadjuvant therapy and direct surgery in IB2/IIA2 cervical adenocarcinoma: a retrospective study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1247-1255.  | 1.7  | 7         |
| 12 | TRPM7 promotes the epithelial $\rightarrow$ mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 106.                     | 8.6  | 90        |
| 13 | Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 742-757.   | 0.9  | 98        |
| 14 | TRPM7 is required for ovarian cancer cell growth, migration and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 547-553.  | 2.1  | 48        |
| 15 | Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3955-3958.  | 1.2  | 27        |